Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRUIN-CLL-314: Pirtobrutinib vs Ibrutinib in CLL/SLL
NCT05254743Phase 3Recruiting
- Sponsor
- Loxo Oncology
- Start
- Jul 2022
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial of pirtobrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (3 arms), sponsored by Loxo Oncology. Primary endpoints: Overall Response Rate Part 1 and Overall Response Rate Part 2. Started Jul 2022; status: recruiting.
02
Drugs
pirtobrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05254743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05254743.